Also thanks to favorable weight loss injections: Sandoz wants to more than double sales
Basel-based generic drug manufacturer Sandoz has set itself ambitious growth targets. However, the problem with Trump's tariff threats remains unresolved. The company still lacks a production facility in the US.
Sandoz, a Basel-based generic drug manufacturer, has set ambitious growth targets, aiming to more than double its revenue by 2035 and increase its adjusted EBITDA margin to over 30%. The company, which was spun off from Novartis and listed on the Swiss stock exchange in October 2023, has seen its stock price more than double since last spring.
Sandoz plans to launch over 100 biosimilars by 2040, including copies of popular weight-loss medications, and expects to become the clear market leader in this area. However, the company still faces challenges, including potential US tariffs on generics and a lack of a US production facility.
Written by urgent.news from NZZ Wirtschaft's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Sandoz will Umsatz bis 2035 mehr als verdoppeln derstandard.at
